For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Idun Pharmaceuticals, Inc.

USPTO Granted Patents = 33

% Expired Patents = 18.2

CIPO Patents = 1

Forward Citations = 298

Loading Chart...

Loading Chart...

27 inventors (with patents filed for the assignee):

Kevin J Tomaselli (15 out of 22 patents)

Steven D Linton (11 out of 11 patents)

Robert J Ternansky (10 out of 35 patents)

4. Lawrence C Fritz (10 out of 11 patents)

5. Donald Karanewsky (9 out of 62 patents)

6. Xu Bai (8 out of 10 patents)

7. Donald S Karanewsky (7 out of 61 patents)

8. Robert Craig Armstrong (6 out of 18 patents)

9. Patricia L Gladstone (4 out of 7 patents)

10. Tilman Oltersdorf (3 out of 7 patents)

11. Teresa Fernandes-Alnemri (3 out of 14 patents)

12. Emad S Alnemri (3 out of 34 patents)

13. Gerald Litwack (3 out of 21 patents)

14. William A Horne (3 out of 3 patents)

15. Jose-Luis Diaz (3 out of 3 patents)

Core Competencies:

Cysteine Proteases

ICE/CED-3 Family

Apoptosis

Inflammation

Dipeptides

Tricyclic Compounds

Polypeptides

NADPH Oxidase

Mch5

Human Bad Polypeptides

Compositions

Methods of Use

33 patents: Sort by Forward Citations

1. 7183260 - C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases (2007-02-27),

2. 7157430 - (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases (2007-01-02),

3. 7053056 - C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases (2006-05-30),

4. 6969703 - Inhibitors of the ICE/ced-3 family of cysteine proteases (2005-11-29),

5. 6897296 - Antibody that specifically binds an Mch5 polypeptide (2005-05-24),

6. 6824991 - Human bad polypeptides, encoding nucleic acids and methods of use (2004-11-30),

7. 6790989 - Inhibitors of the ICE/ced-3 family of cysteine proteases (2004-09-14),

8. 6762045 - Membrane derived caspase-3, compositions comprising the same and methods of use therefor (2004-07-13),

9. 6693096 - Treatment of inflammation-associated disorders using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2004-02-17),

10. 6610683 - Treatment of infectious disease using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2003-08-26),

11. 6544951 - C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases (2003-04-08),

12. 6531467 - Inhibition of inflammation using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2003-03-11),

13. 6528506 - Inhibition of apoptosis using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2003-03-04),

14. 6525024 - Inhibitors of the ICE/ced-3 family of cysteine proteases (2003-02-25),

15. 6518032 - Rapid methods for identifying modifiers of cellular apoptosis activity (2003-02-11),

Idun Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapies for autoimmune and inflammatory diseases. The company specializes in harnessing advanced scientific research to create novel treatments that target underlying disease mechanisms. With a commitment to improving patient outcomes, Idun leverages its expertise in molecular biology and pharmacology to advance its pipeline of therapeutics, aiming to address significant unmet medical needs in the healthcare landscape.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

33 Patents

#192 in San Diego, CA

#2,458 in California

#10,288 in US

#20,112 in the World

San Diego, CA, United States of America

Idun Pharmaceuticals, Inc.

Forward Citations = 298

27 inventors:

Kevin J Tomaselli (15 out of 22 patents)

Steven D Linton (11 out of 11 patents)

Robert J Ternansky (10 out of 35 patents)

4. Lawrence C Fritz (10 out of 11 patents)

5. Donald Karanewsky (9 out of 62 patents)

Please report any incorrect information to [email protected]

Loading…